Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)

Prior treatment

• Participation in any clinical trial within 30 days prior to enrolment
• Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment
• Continuous use of oral (\>5 mg prednisolone/day OR \>4 mg methylprednisolone/day) OR intravenous corticosteroids
• Use of continuous oxygen therapy
• Actual or previous use of biologics for asthma treatment in the past 12 months

Other illness

• Another respiratory condition, apart from asthma or COPD, that may interfere with the effectiveness of the treatment studied AND/OR another important clinical situation that may interfere with patient's compliance with the treatment.
• Any malignant disease in the last 5 years
• Tuberculosis (active or anamnestic)

Other

• All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC

• Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
• Patients ≥ 18 years of age in ambulatory care
• Uncontrolled asthma according to the physician's clinical assessment despite the use of:
  • LABA and high dose ICS or
  • LABA and high-dose ICS + LAMA multi-inhaler triple therapy for a minimum of three months.
• Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC :
  • at least on exacerbation, requiring systemic (oral or intravenous) corticosteroids in the previous 12 months
  • uncontrolled asthma (ACT≤15) or partially controlled asthma (15\<ACT\<20)
  • FEV1\<80% at baseline
• Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 1 week prior to OR on the day of study inclusion
• Patient provided written, informed consent to study participation